DexCom, Inc. is a medical device company focused on the design, development and
commercialization of continuous glucose monitoring systems for ambulatory use by
people with diabetes and for use by healthcare providers in the hospital for the
treatment of patients with and without diabetes. Unless the context requires
otherwise, the terms �we,� �us,� �our,� the �company,� or �DexCom� refer to
DexCom, Inc. and its subsidiaries.
Ambulatory Product Line: SEVEN� PLUS, DexCom G4� and DexCom G4� PLATINUM
We received approval from the Food and Drug Administration (�FDA�) and
commercialized our first product in 2006. In 2007, we received approval and
began commercializing our second generation system, the DexCom SEVEN. We no
longer market or provide support for the DexCom SEVEN system.